1 / 4

Ethan Basch , M.D. Memorial Sloan-Kettering Cancer Center POTENTIAL EARLY COLLABORATIONS

PRO-CTCAE Face-To-Face Meeting #2 Advancing the Science of Adverse Symptom Monitoring in Cancer Treatment Trials. Ethan Basch , M.D. Memorial Sloan-Kettering Cancer Center POTENTIAL EARLY COLLABORATIONS May 24, 2010 National Cancer Institute. Industry/Commercial. Astra-Zeneca Merck

borka
Download Presentation

Ethan Basch , M.D. Memorial Sloan-Kettering Cancer Center POTENTIAL EARLY COLLABORATIONS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PRO-CTCAE Face-To-Face Meeting #2Advancing the Science of Adverse Symptom Monitoring in Cancer Treatment Trials Ethan Basch, M.D. Memorial Sloan-Kettering Cancer Center POTENTIAL EARLY COLLABORATIONS May 24, 2010 National Cancer Institute

  2. Industry/Commercial • Astra-Zeneca • Merck • Genentec • McKesson • NavigatingCancer.com

  3. Cooperative Group Trials • CALGB 360901: Memantine as neuroprotector for PCI in SCLC (Ahles) • NCCTG 0949/CALGB 81002: FOLFOX/Bev vs. Fluoropyrimidine/Bev in metastatic colorectal cancer in older patients (Jackson, Grothey) • CALGB 80903: Ph3 chemo +/- liver cytoreduction in liver metastasis-dominant colorectal cancer (Solomon/Zafar) • CALGB 80702: Ph3 adjuvant FOLFOX + celecoxib or placebo in resected stage III colon cancer (Meyerhardt/Shields) • SWOG XXX: Diarrhea evaluation (Monipoor) • CALGB 81001: Ph2 neoadjuvant FOLFOX +/- RT in good-risk rectal cancer (Schrag) • RTOG 1016: Favorable risk H/N cancer (Trotti/Ringash)

  4. Academic • DFCI: Lung cancer symptoms (Cooley R01) • University of Tokyo: Japanese translation (Kuroda/Yamaguchi) • MSKCC: Oropharynx cancer longitudinal QOL (Baxi/Pfister) • Johns Hopkins: Patient preferences in lung cancer (Bridges)

More Related